Anderson C, White J, Abubakar I Raising standards in UK TB control: introducing cohort review. Thorax. 2014; 69:(2)187-189

Angen MJ. Evaluating interpretive inquiry: reviewing the validity debate and opening the dialogue. Qual Health Res. 2000; 10:(3)378-395

Arlinghaus KR, Johnston CA. Advocating for behavior change with education. Am J Lifestyle Med. 2018; 12:(2)113-116

Atkins S, Lewin S, Jordaan E, Thorson A. Lay health worker-supported tuberculosis treatment adherence in South Africa: an interrupted time-series study. Int J Tuberc Lung Dis. 2011; 15:(1)84-89

Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977; 84:(2)191-215

Baral SC, Karki DK, Newell JN. Causes of stigma and discrimination associated with tuberculosis in Nepal: a qualitative study. BMC Public Health. 2007; 7:(1)

Bayer R, Dupuis L. Tuberculosis, public health, and civil liberties. Annu Rev Public Health. 1995; 16:(1)307-326

Behzadifar M, Mirzaei M, Behzadifar M, Keshavarzi A, Behzadifar M, Saran M. Patients' experience of tuberculosis treatment using directly observed treatment, short-course (DOTS): a qualitative study. Iran Red Crescent Med J. 2015; 17:(4)

Centre for Pharmacy Postgraduate Education. Consultation skills for Pharmacy practice: taking a patient-centred approach. 2015. (accessed 23 June 2022)

Chang S-H, Cataldo JK. A systematic review of global cultural variations in knowledge, attitudes and health responses to tuberculosis stigma. Int J Tuberc Lung Dis. 2014; 18:(2)168-173

Clarke V, Braun V. Successful qualitative research: a practical guide for beginners.London: Sage; 2013

Chisholm D, Sweeny K, Sheehan P Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry. 2016; 3:(5)415-424

Craig GM, Zumla A. The social context of tuberculosis treatment in urban risk groups in the United Kingdom: a qualitative interview study. Int J Infect Dis. 2015; 32:105-110

Cremers AL, de Laat MM, Kapata N, Gerrets R, Klipstein-Grobusch K, Grobusch MP. Assessing the consequences of stigma for tuberculosis patients in urban Zambia. PLoS One. 2015; 10:(3)

Demissie M, Getahun H, Lindtjørn B. Community tuberculosis care through ‘TB clubs’ in rural North Ethiopia. Soc Sci Med. 2003; 56:(10)2009-2018

Doherty AM, Kelly J, McDonald C, O'Dywer AM, Keane J, Cooney J. A review of the interplay between tuberculosis and mental health. Gen Hosp Psychiatry. 2013; 35:(4)398-406

Gupta S, Berg D, de Lott F, Kellner P, Driver C. Directly observed therapy for tuberculosis in New York City: factors associated with refusal. Int J Tuberc Lung Dis. 2004; 8:(4)480-485

Helgeson VS, Cohen S. Social support and adjustment to cancer: reconciling descriptive, correlational, and intervention research. Health Psychol. 1996; 15:(2)135-148

Janmeja AK, Das SK, Bhargava R, Chavan BS. Psychotherapy improves compliance with tuberculosis treatment. Respiration. 2005; 72:(4)375-380

Lincoln Y, Guba E. Naturalistic inquiry.Newbury Park (CA): Sage Publications; 1985

Macq J, Solis A, Martinez G, Martiny P. Tackling tuberculosis patients' internalized social stigma through patient centred care: an intervention study in rural Nicaragua. BMC Public Health. 2008; 8:(1)

Mason PH, Sweetland AC, Fox GJ, Halovic S, Nguyen TA, Marks GB. Tuberculosis and mental health in the Asia-Pacific. Australas Psychiatry. 2016; 24:(6)553-555

McLaughlin H. Understanding social work research, 2nd edn. London: Sage Publications; 2012

Mekonnen HS, Azagew AW. Non-adherence to anti-tuberculosis treatment, reasons and associated factors among TB patients attending at Gondar town health centers, Northwest Ethiopia. BMC Res Notes. 2018; 11:(1)

National Institute for Health and Care Excellence. Tuberculosis. NICE guideline NG33. 2016. (accessed 23 June 2022)

Paterick TE, Patel N, Tajik AJ, Chandrasekaran K. Improving health outcomes through patient education and partnerships with patients. Baylor University Medical Center Proceedings. 2017; 30:(1)112-113

Public Health England. Tuberculosis (TB): collaborative strategy for England 2015 to 2020. 2015. (accessed 23 June 2022)

Public Health England. Tackling TB in under-served populations: a resource for TB control boards and their partners. 2019. (accessed 23 June 2022)

Rapport F, Storey M, Porter A Qualitative research within trials: developing a standard operating procedure for a clinical trials unit. Trials. 2013; 14:(1)

Reichmann L, Hopkins-Tanne J. Timebomb: The global epidemic of multi-drug resistant tuberculosis.New York (NY): McGraw-Hill; 2002

Ritchie J, Lewis J, Nicholls C, Ormston R. Qualitative research practice: a guide for social science students and researchers.London, UK: Sage Publications; 2013

Royal College of Nursing. A case management tool for TB prevention, care and control. 2019. (accessed 23 June 2022)

Sagbakken M, Gunnar B, Frich J. A qualitative study of patients' and health professionals' experiences with tuberculosis treatment in Norway. Humiliation or care?. Scand J Caring Sci. 2012; 26:313-323

Sweetland A, Oquendo M, Wickramaratne P, Weissman M, Wainberg M. Depression: a silent driver of the global tuberculosis epidemic. World Psychiatry. 2014; 13:(3)325-326

Tian J-H, Lu Z-X, Bachmann MO, Song F-J. Effectiveness of directly observed treatment of tuberculosis: a systematic review of controlled studies. Int J Tuberc Lung Dis. 2014; 18:(9)1092-1098

UK Health Security Agency. Tuberculosis in England: 2021 report. 2021. (accessed 23 June 2022)

Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving chronic illness care: translating evidence into action. Health Aff. 2001; 20:(6)64-78

World Health Organization. What is DOTS? A guide to understanding the WHO-recommended TB control strategy known as DOTS. 1999. (accessed 23 June 2022)

World Health Organization. Tuberculosis. Key facts. 2021. (accessed 23 June 2022)

Wright CM, Westerkamp L, Korver S, Dobler CC. Community-based directly observed therapy (DOT) versus clinic DOT for tuberculosis: a systematic review and meta-analysis of comparative effectiveness. BMC Infect Dis. 2015; 15:(1)210-221

Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ, Tatley M. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet. 1998; 352:(9137)1340-1343

Patients' perceptions and experiences of directly observed therapy for TB

07 July 2022
Volume 31 · Issue 13



To understand patients' perceptions and experiences of directly observed therapy (DOT) for tuberculosis treatment in the UK.


Patients receiving DOT as part of their TB treatment participated in semi-structured and audio-recorded interviews. Data were analysed using a framework approach.


Non-adherence was driven by socio-cultural, mental health, employment and discrimination factors. Patients valued DOT for its support and social connection but those in employment feared it could lead to disclosure and social discredit.


TB patients experience social isolation and fear discrimination. DOT offers a degree of social connection and support for marginalised patients but fails to tackle fundamental barriers to adherence such as mental health issues, addictions, housing and discrimination. Practice implications: Flexible patient-centred methods of DOT should be offered throughout patients' treatment. Research into multi-agency responsibility for promoting adherence needs to be commissioned, implemented and evaluated. Telemedicine and nurse-led clinics may improve access to care and improve patient experience.

Tuberculosis (TB) is caused by a bacterium (Mycobacterium tuberculosis). When people with active TB in their lungs or throat cough, sneeze or spit, they can propel TB germs into the air which can be breathed in by others. A person need only inhale a single bacterium to become infected. TB usually affects the lungs, causing consolidation and tissue destruction, but can spread from the lungs to other parts of the body such as the spine, other organs and lymph nodes, causing serious infection. People with active TB in their lungs can infect 5–15 other people through close contact over the course of a year. Without proper treatment, 45% of people with active TB who are HIV negative and nearly all people with active TB who are HIV positive will die (World Health Organization (WHO), 2021).

Drug-sensitive TB is treated with a combination of antibiotics, usually 6 months of rifampicin and isoniazid augmented with ethambutol and pyrazinamide for the first 2 months. Severe cavitary pulmonary disease may need a longer course of treatment (9–12 months) and nearly all patients will experience undesirable side effects ranging from fatigue, nausea and vomiting through to rashes and liver toxicity. Drug-resistant strains of TB, however, require longer courses of treatment of between 9 and 24 months and include the use of second-line antibiotics with profound side-effects such as ototoxicity, gastrointestinal and central nervous system disturbances, dermatological changes and arthralgia.

Register now to continue reading

Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • Unlimited access to the latest news, blogs and video content